DexCom, Inc. vs Merck & Company, Inc. — Stock Comparison
DexCom, Inc. (DXCM) and Merck & Company, Inc. (MRK) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
DexCom, Inc. clearly outscores Merck & Company, Inc. on Q·Score (8.3 vs 6 out of 10), led by Quality (9.3 vs 4.4) and Growth (8.9 vs 5.1). Analyst consensus targets imply greater upside for DXCM (+16.9%) than for MRK (+6.7%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 38% return on equity and 20% profit margins.
68% of 28 covering analysts have a positive rating.
⚠ weak profitability metrics drag quality score.
Analyst Consensus
Fundamentals
Frequently Asked Questions
DXCM vs MRK: which stock scores better overall?
Based on Q·Score, DexCom, Inc. (DXCM) scores 8.3/10 versus Merck & Company, Inc. (MRK) at 6/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: DXCM or MRK?
DexCom, Inc. (DXCM) scores higher on Growth (8.9/10 vs 5.1/10). DexCom, Inc. reports revenue growth (13.1% YoY) while Merck & Company, Inc. reports (4.7% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is DXCM or MRK more attractively valued?
DexCom, Inc. (DXCM) scores higher on Valuation (7/10 vs 7/10). DXCM trades at 26.3× P/E versus MRK at 16.2×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about DXCM vs MRK?
There are 26 analysts covering DXCM with a consensus price target of $96.19, and 26 analysts covering MRK with a consensus target of $159.60. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: DXCM or MRK?
DexCom, Inc. (DXCM) scores higher on Quality (9.3/10 vs 4.4/10). Net profit margin: DXCM at 20.1%, MRK at 3.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: DXCM or MRK?
DexCom, Inc. (DXCM) scores higher on Financial Health (7.6/10 vs 7/10). Market beta: DXCM at 1.48, MRK at N/A. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of DXCM and MRK?
DexCom, Inc. (DXCM) has a market capitalisation of $31.1B, while Merck & Company, Inc. (MRK) has a market cap of $368.9B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do DXCM or MRK pay dividends?
DXCM does not currently pay a dividend, while MRK pays a dividend yield of 2.32%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →